In a special report in The Lancet [1], researchers from Queen Mary, University of London (UK) argue that pending cases against India's patent laws threaten public health and misinterpret international intellectual property agreements.
The report, which is published today (Monday), highlights legal challenges by two pharmaceutical companies, Bayer and Novartis, to key provisions of India's Patents Act. Bayer's appeal was heard last week, and the Indian Supreme Court is due to hear Novartis' appeal tomorrow (11th September).